Robeco Institutional Asset Management B.V. Sells 27,012 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Robeco Institutional Asset Management B.V. reduced its position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 31.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 60,036 shares of the biotechnology company's stock after selling 27,012 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.13% of United Therapeutics worth $13,201,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the business. GAMMA Investing LLC acquired a new stake in United Therapeutics during the 4th quarter worth about $43,000. C M Bidwell & Associates Ltd. acquired a new position in shares of United Therapeutics during the third quarter valued at approximately $91,000. Blue Trust Inc. grew its holdings in shares of United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company's stock worth $114,000 after buying an additional 46 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in United Therapeutics by 31.2% in the 4th quarter. Quadrant Capital Group LLC now owns 581 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 138 shares during the last quarter. Finally, CWM LLC lifted its position in United Therapeutics by 45.7% during the fourth quarter. CWM LLC now owns 670 shares of the biotechnology company's stock worth $147,000 after buying an additional 210 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In related news, EVP Paul A. Mahon sold 6,000 shares of the business's stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $236.45, for a total value of $1,418,700.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $8,680,079.50. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Paul A. Mahon sold 6,000 shares of the business's stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $236.45, for a total transaction of $1,418,700.00. Following the completion of the transaction, the executive vice president now owns 36,710 shares of the company's stock, valued at approximately $8,680,079.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $265.48, for a total transaction of $955,728.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $34,512.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 150,140 shares of company stock worth $36,051,162. Insiders own 12.50% of the company's stock.

United Therapeutics Price Performance

UTHR stock traded up $2.04 during trading hours on Friday, hitting $274.26. 329,299 shares of the stock traded hands, compared to its average volume of 578,775. United Therapeutics Co. has a one year low of $204.44 and a one year high of $275.00. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The company has a market cap of $12.17 billion, a P/E ratio of 12.97 and a beta of 0.54. The stock has a 50-day simple moving average of $244.01 and a 200 day simple moving average of $232.40.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts' consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business had revenue of $677.70 million during the quarter, compared to analyst estimates of $620.31 million. During the same quarter last year, the company posted $4.86 EPS. United Therapeutics's revenue for the quarter was up 33.7% on a year-over-year basis. Equities analysts forecast that United Therapeutics Co. will post 24.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on UTHR shares. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. SVB Leerink started coverage on United Therapeutics in a research report on Monday, February 5th. They set an "outperform" rating and a $330.00 price target on the stock. Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research report on Monday, February 5th. Wedbush restated an "outperform" rating and issued a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. Finally, Oppenheimer raised their price target on United Therapeutics from $375.00 to $400.00 and gave the company an "outperform" rating in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, United Therapeutics has an average rating of "Buy" and a consensus price target of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.